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Determination of the molecules that regulate astrocyte development has been hindered by the paucity of markers that identify astrocytic
precursors in vivo. Here we report that the chondroitin sulfate proteoglycan aggrecan both regulates astrocyte development and is expressed by
embryonic glial precursors. During chick brain development, the onset of aggrecan expression precedes that of the astrocytic marker GFAP and is
concomitant with detection of the early glial markers GLAST and glutamine synthetase. In co-expression studies, we established that aggrecan-rich
cells contain the radial glial markers nestin, BLBP and GLAST and later in embryogenesis, the astroglial marker GFAP. Parallel in vitro studies
showed that ventricular zone cultures, enriched in aggrecan-expressing cells, could be directed to a GFAP-positive fate in G5-supplemented
differentiation media. Analysis of the chick aggrecan mutant nanomelia revealed marked increases in the expression of the astrocyte
differentiation genes GFAP, GLAST and GS in the absence of extracellular aggrecan. These increases in astrocytic marker gene expression could
not be accounted for by changes in precursor proliferation or cell death, suggesting that aggrecan regulates the rate of astrocyte differentiation.
Taken together, these results indicate a major role for aggrecan in the control of glial cell maturation during brain development.
© 2007 Elsevier Inc. All rights reserved.Keywords: Aggrecan; Astrocyte; Nanomelia; Gliogenesis; Precursors; Extracellular matrixIntroduction
The environment in which neurons, glial cells and their
precursors proliferate, migrate, differentiate and survive
becomes progressively more complex as the central nervous
system (CNS) develops. A key component of this complexity,
and one increasingly recognized as a regulator of cell behavior,
is the extracellular matrix (ECM). Chondroitin sulfate proteo-
glycans (CSPGs), the most abundant proteoglycans in the CNS,
are a major component of brain ECM. To date, study of CSPG
function has focused principally on their roles in late events in
brain development, particularly axon outgrowth (Brittis and
Silver, 1995; Faissner et al., 1994), and on their importance⁎ Corresponding author. Fax: +1 773 702 9234.
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doi:10.1016/j.ydbio.2007.12.014for axon regeneration in the mature brain (Johnson, 1993;
Morgenstern et al., 2002). For example, in studies of the
dopaminergic nigrostriatal system and spinal cord, degradation
of CSPG glycosaminoglycan side chains by chondroitinase
enhances axon regeneration in vivo (Barritt et al., 2006;
Bradbury et al., 2002; Cafferty et al., 2007; Moon et al.,
2001; Yick et al., 2000), and in related work, release of CSPGs
from their anchorage in the extracellular matrix by hyaluroni-
dase treatment has been shown to enhance local sprouting of cut
axons (Moon et al., 2003). By contrast, even though CSPGs are
also abundant in embryonic brain, their possible contribution to
neural patterning and cell type differentiation has received much
less attention.
The major CSPGs expressed during brain development are
the aggrecan family members neurocan, brevican, versican and
aggrecan. These proteoglycans share an N-terminal IgG-like
globular domain that binds hyaluronan, a central chondroitin
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important for intracellular trafficking (Domowicz et al., 2000).
Previous studies of CSPG expression during CNS development
have found that neurocan is expressed by neurons and
astrocytes (Margolis and Margolis, 1997), versican is found in
oligodendrocyte precursors and neurons (Asher et al., 2002;
Lebaron, 1996; Schmalfeldt et al., 2000; Yamagata and Sanes,
2005) and brevican is enriched in cells in the embryonic
ventricular zone (Jaworski et al., 1995). To date, no brain-
specific developmental phenotypes due to the loss of aggrecan
family CSPGs have been reported (Hartmann and Maurer,
2001; Rauch et al., 2005). Perhaps the most striking finding in
this regard has been the absence of any obvious effect on early
neural development from quadruple gene targeting of neurocan,
brevican and tenascin C and R (Brakebusch et al., 2002;
Hartmann and Maurer, 2001; Rauch et al., 2005; Zhou et al.,
2001).
Among the CSPGs in brain, aggrecan exhibits the most
dynamic pattern of developmental gene regulation. In chick
embryos, aggrecan mRNA expression brain is detected by
embryonic days 6–7 (E6–7), peaks at E14–15 and is nearly
extinguished by hatching (Krueger et al., 1992; Li et al., 1996).
Biochemical analysis of brain aggrecan has shown that it is
distinct from the aggrecan of cartilage, which contains keratan
sulfate and has a larger hydrodynamic size, probably due to a
higher content of chondroitin sulfate (Krueger et al., 1992; Li
et al., 1996). Functional studies of aggrecan to date have fo-
cused upon cartilage development. Spontaneously occurring
aggrecan mutants, nanomelia in chickens and cmd in mouse,
have profound defects in skeletal growth (Kimata et al., 1981;
Landauer, 1965; Rittenhouse et al., 1978). Brain defects in
aggrecan-deficient lines have not been previously analyzed in
part because mutants die at birth. However, one in vitro study of
chick forebrain cultures has found that dissociated nanomelic
cells on poly-lysine plates form fewer and smaller spontaneous
neuronal aggregates than do wild type cells (Domowicz et al.,
2003). This observation raises the possibility that, unlike
neurocan and brevican, aggrecan may have an important role in
early neuronal development.
We report here our observations on the development and
cellular expression of brain aggrecan and the functional
consequences of aggrecan deficiency studied in the nanomelic
chick. Our findings establish that aggrecan is expressed in glial
precursors and is required for normal astrocyte differentiation.Materials and methods
Wild type (wt) fertilized White Leghorn chicken eggs were purchased
from Sharp Sales (West Chicago, IL). Fertilized eggs from heterozygous
nanomelic (+/nm) crosses were provided by Dr Louis Pierro and Ms Karen
Morè of the Department of Animal Genetics, University of Connecticut
(Storrs, CT). Eggs were incubated at 37.9 °C at 60% humidity in a Midwest
incubator with automatic egg turning and regularly hatched at 21 days of
incubation. Embryonic nanomelic homozygotes could be identified from E8
onwards by morphology. In all experiments, both White Leghorn embryos
and embryos of normal progeny from the nanomelic heterozygous crosses
(flock mates, fm) were tested as controls. No differences between these two
set of controls were found in the levels, distributions and developmentalregulation of any messages assayed by in situ hybridization or Northern
blotting.
mRNA in situ hybridization
Heads from E3–E19 chick embryos were fixed in 4% paraformaldehyde in
phosphate-buffered saline (PBS) and the harvested brains were processed for
whole mount in situ hybridization as described (Grove et al., 1998). For tissue
section analysis, brains were sunk in 20% sucrose–10% formalin in PBS,
embedded in gelatin and cut at a thickness of 40 μm on a sledge microtome.
Sections were mounted on SuperFrost/Plus microscope slides and processed for
non-radioactive in situ hybridization. Sections of E12 and younger brain tissue
were permeabilized by two 15-minute treatments with a detergent mixture of 1%
NP-40, 1% SDS, 0.5% deoxycholate in 1 mM EDTA/150 mM NaCl/50 mM
Tris–HCl (pH 8). Older tissue was digested for 15 min with 1 μg/ml proteinase
K in PTw (PBS with 1% Tween-20). Slides were then rinsed twice in PTw, post-
fixed for 15 min in 4% paraformaldehyde-PTw and rinsed in PTw.
Hybridizations with digoxigenin (DIG)-labeled riboprobes were conducted
overnight at 70 °C in 50% formamide, 5× SSC, 1% SDS, with tRNA, acetylated
BSA and heparin added as carriers. Four 30-minute post-hybridization washes
were performed at 70 °C in solution X (50% formamide, 2× SSC, 1% SDS).
DIG-labeled RNA duplexes were detected with NBT-BCIP histochemistry after
incubation with an alkaline phosphatase/anti-DIG Fab conjugate.
Two-color fluorescent in situ hybridization (FISH) was performed on E9
chick brain coronal sections with FITC- and DIG-labeled riboprobes. Sections
were permeabilized by treatment with proteinase K (1 μg/ml) for 20 min. After
post-hybridization washes, bound FITC was detected with a peroxidase-
conjugated anti-FITC antibody (Perkin Elmer) and incubation with the
peroxidase substrate FITC-tyramide. Following inactivation at 70 °C, the
second probe was localized with a peroxidase-conjugated anti-DIG antibody and
Cy5-tyramide (Roche). Fluorescence was studied with a Leica SP2 spectral
confocal microscope in the BSD Digital Light Microscopy Core Facility of the
University of Chicago Cancer Research Center.
cDNAs
Aggrecan gene expression was analyzed with riboprobes derived from a
690 bp fragment of exon 12 of the chicken aggrecan gene, which encodes the
chondroitin sulfate domain of the aggrecan core protein and bears no sequence
identity to other aggrecan family members. cDNAs for GLAST/SLC1A3 (nt
1053–1765 of XM425011), BLBP/FABP7 (nt 46–582 of NM205308), nestin/
transitin/NES (nt 130–617 of NM205033), FGFR3/cek2 (nt 1164–1491 of
NM205509) and PTGS2/COX2 (nt 1013–1547 of M64990) were obtained by
PCR from a chick E12 brain cDNA using specific primers based on deposited
sequence. Brevican/BCAN (2034–2731 of XM423655) and GFAP (621–1146
of XM418091) cDNA fragments were generated using degenerate primers based
on the sequences of the mammalian orthologs. The degenerate oligonucleotides
were designed with the aid of the Blocks and CODEHOP (COnsensus-
DEgenerate Hybrid Oligonucleotide Primers) programs (Rose et al., 1998). All
isolated PCR products were ligated into the pCRII-dual promoter vector
(Invitrogen) for riboprobe synthesis. Glutamine synthetase, proteolipid protein
1, tenascin C and class III beta-tubulin were studied with cDNAs provided by
W.-K. Chen (GLUL), J. Thomas (PLP1), R. Chiquet-Ehrismann (TNC) and D.
Cleveland (TUBB3).
Northern blots
Total RNA was extracted from wt and nm brains using Trizol reagent
(Invitrogen). RNA (10 μg per lane) was electrophoresed in a denaturing 1.2%
agarose-formaldehyde gel and transferred to Nytran SuperCharge (Schleicher
and Schuell) membranes by TurboBlotter rapid downward transfer. Hybridiza-
tion was performed using QuikHyb solution (Stratagene). Radiolabeled probes
were prepared using the Rediprime system (Roche). Following hybridization,
the nylon membranes were washed twice with 2× SSC/0.05% SDS for 30 min at
room temperature and twice with 0.1× SSC/0.1% SDS for 30 min at 58 °C.
Autoradiography was performed overnight at −70 °C with Kodak MR2 film.
Bands were quantified with the Quantity One image analysis software (Bio-
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GAPDH mRNA level was used as the internal standard for loading differences.
Immunostaining and proliferation
After mRNA in situ hybridization, sections were stained with the
monoclonal antibody S103L that recognized the core protein of chick aggrecan
(Krueger et al., 1990) using a peroxidase conjugated anti-rat IgG secondary
antibody. Peroxidase activity was then detected using the ImmunoHisto
peroxidase detection kit (Pierce). For immunocytochemistry after mRNA
FISH, sections were permeabilized for 40 min with a detergent mixture
consistent of 1%NP-40, 1%SDS, 0.5% deoxycholate in 1 mM EDTA/150 mM
NaCl/50 mM Tris–HCl (pH 8) and with proteinase K (1 μg/ml) for 7 min at
room temperature. Anti-GFAP (Chemicon) and anti-BLBP (Chemicon) were
used as primary antibodies at a 1:500 dilution. For proliferation assays, BrdU
(1.6 mg/100 μl) was applied to the vitelline membrane of E18 eggs 3 h prior to
tissue harvest. Tissue was then fixed, embedded, sectioned and processed for
immunocytochemistry using an anti-BrdU IgG (BD Bioscience) primary
antibody and alkaline phosphatase conjugated anti-rabbit IgG (Roche,
Germany) secondary antibody. As an alternative method to determine mitotic
levels, the mitotic nuclei were identified by immunocytochemistry with anti-
phospho-histone H3 (Ser10) polyclonal antibody (pHH3) (Upstate Biotechnol-
ogy) in paraffin embedded sections from E15 and E18 cerebellum. An FITC-
conjugated anti-rabbit IgG was used as secondary antibody and DAPI was
utilized to counterstain the nuclei. Positive BrdU and pHH3 mitotic nuclei from
two brains were counted in cerebellar white matter using ImageJ software and
data were analyzed for statistical significance using the Student's t-test.
Ventricular zone cultures
Midbrain ventricular zone (VZ) was dissected from E11 chick midbrain and
mechanically dissociated into single cells. Cells were plated on Primaria dishes
(Becton-Dickinson) in 10% fetal calf serum/DMEM with EGF (40 ng/ml) and
bFGF (40 ng/ml). Some cultures were switched to F12/DMEM media
supplemented with G5 and 1.5 μM trans-retinoic acid after 7 days in vitro.
All cultures were harvested for study 9 days after plating. Tissue culture reagents
were purchased from Invitrogen.Fig. 1. Aggrecan whole mount gene expression demonstrates that a patterned
organization to the chick brain VZ continues after neurogenesis is largely
complete. (A) Midline cut displays heterogeneities in aggrecan mRNA distri-
butions in the right brain VZ of the E8 chick embryo. Dorsal is to the top and
rostral is to the left. Arrow marks the prospective olfactory bulb. (B, C) Dorsal
view of late E7 (B) and E8 (C) hindbrains oriented with rostral to the top. Arrow
in panel B points to labeling in rhombomere 4. (D) Dorsal view of E8 ventral
midbrain, with the prospective midbrain tectum resected. Arrows point to
arcuate territories in VZ gene expression patterns. Arrowhead identifies dense
labeling of the isthmus. di, diencephalon; hb, hindbrain; mb, midbrain; ob, obex;
tel, telencephalon.Results
Aggrecan gene expression in chick embryogenesis
Aggrecan mRNA in brain was first detected by in situ
hybridization at E6 (HH st 30). By early E7, aggrecan message,
restricted to the ventricular zone (VZ), presented a richly
patterned distribution, with lateral and medial longitudinal
stripes in hindbrain, tufts in midbrain and diencephalon and a
focus in rostroventral telencephalon marking the prospective
olfactory bulb (Fig. 1). Over the next day, AGC brain expression
levels increased, revealing rhombomeric territories in hindbrain,
arcuate territories in ventral midbrain and bands in forebrain.
Superimposed on these patterns were strong rostral/high caudal/
low gradients of AGC levels in telencephalon and, separately, in
midbrain (Fig. 1A). By E8, AGC gene expression was no longer
restricted to the VZ but included aggrecan-rich cells in
hindbrain and near the meso-diencephalic junction that
appeared to be migrating from the VZ deep into the mantle
layer (Fig. 2A).
Although the complex pattern of initial AGC gene expression
could suggest a role for the proteoglycan in neuronal patterning,
the relatively late onset and initial VZ restriction of AGC raise
the intriguing possibility of involvement in gliogenesis. Anastroglia association was further suggested by comparisons of
E8 hindbrain AGC cross-sections with cross-sections hybri-
dized with markers of neurons and glia (Fig. 2). The E8 AGC
hindbrain pattern of medial and lateral streams of cells
extending from the ventricle (Fig. 2A) was paralleled by the
gene expression distributions of the radial glial marker GLAST
(high affinity, sodium-dependent L-glutamate/L-aspartate trans-
porter) (Hartfuss et al., 2001; Shibata et al., 1997). Partially
overlapping but clearly similar medial and lateral streams were
also demonstrated with the glial markers glutamine synthetase
(GLUL), brain lipid binding protein (BLBP), FGF receptor 3
(FGFR3) and nestin (NES) (Figs. 2C, D and H; Fig. S1)
Fig. 2. Medial and lateral streams of aggrecan-rich cells in E8 hindbrain cross-sections follow a pattern seen with astroglial markers and not markers of postmitotic
neurons or oligodendrocytes. (A) Aggrecan gene expression, showing labeled cells (arrows) that appear to be migrating from the VZ. (B–D) Similarly positioned
streams (but ones differing greatly in their density of labeling) are identified with the astrocyte markers GLAST (B), GLUL (C) and BLBP (D). (E, F) Labeling of VZ
and medial and lateral streams is not seen with the neuronal marker class III beta-tubulin/TUBB3 (E) or the oligodendrocyte marker PLP1 (F). (G, H) Gene expression
distributions of the intermediate filament nestin/NES (F) and the aggrecan family member brevican/BCAN (H) are more extensive than those of aggrecan but include
key features such as strong VZ labeling. No hybridization signal for the intermediate filament gene GFAP (glial fibrillary acidic protein) was detected at this stage (not
shown).
117M.S. Domowicz et al. / Developmental Biology 315 (2008) 114–124(Hemken et al., 1997; Lee and Cole, 2000; Napier et al., 1999;
Pringle et al., 2003) and another member of the aggrecan family,
brevican (Fig. 2G). In contrast, labeling of the VZ and the
medial and lateral streams was not seen with markers of
postmitotic neurons (class III beta-tubulin, TUBB3; Fig. 2E)
or prospective oligodendrocytes (proteolipid protein-1, PLP1;
Fig. 2F).
By E12 AGC mRNA was much more widely distributed in
the mantle layer. Its pattern of expression frequently reflectedFig. 3. Aggrecan gene expression follows the distributions of glial markers in
auditory relay nuclei of the chick E12 hindbrain. (A–D) Serially adjoining cross-
sections probed for the expression of aggrecan/AGC (A), the neuronal marker
TUBB3 (B) and the glial markers tenascin-C/TNC (C) and glutamine
synthetase/GLUL (D). Asterisk in panel B marks the nucleus magnocellularis,
which does not express AGC and is free of the astrocyte markers TNC and
GLUL. MeV, medial vestibular nucleus.nuclear boundaries but overlapped the distribution of glial
markers rather than neuronal markers when the two markers
diverged. Fig. 3 documents in serial sections the similarity of
expression territories among AGC, the glial enzyme GLUL and
tenascin C (TNC), an extracellular matrix molecule expressed
by radial glial cells, astroglial precursors (Bartsch et al., 1995;
Yuasa, 2001) and cultured oligodendrocyte precursors (Gar-
wood et al., 2004). AGC expression patterns were not, however,
identical to those of the glial mRNA markers, suggesting that
aggrecan may identify a subset of these cells.
Quantitative analysis of brain mRNA demonstrated that
relative AGC levels peak around E15 and decline sharply
thereafter (Fig. 4). Comparison of the AGC temporal profile
with that of a battery of glial markers suggests that any glial role
for AGC would involve glial precursor development. The rise in
AGC levels from E8 to E15 closely parallels that of GLAST and
precedes the upregulation of GLUL expression and the
expression onset of the mature astroglial marker GFAP. From
E18 to E21, when AGC levels are dropping, the glial marker
mRNAs GLAST, GLUL and GFAP are attaining their maximal
levels of expression, which are maintained in the juvenile chick
brain. The low level of hatchling brain AGC may reflect a
residual role for aggrecan in glial function. Alternatively, it
could reflect a shift in the cellular expression of AGC mRNA to
neurons. In support of the latter possibility, postnatal expression
of aggrecan in the mouse has been associated with perineuronal
nets and neuronal nuclei (Carulli et al., 2007; Dino et al., 2006;
Matthews et al., 2002; McRae et al., 2007; Popp et al., 2003)
and we have preliminary evidence for a neuronal pattern of
AGC gene expression in the hatchling hindbrain (not presented).
Fig. 4. Time-series histogram depiction of quantitative Northern blot data on
brain aggrecan (AGC) levels compared with those of a panel of early and late
astroglial markers (GLAST, GLUL, GFAP). Blots of total RNA isolated from
whole brains at the indicated ages were hybridized with message-specific [32P]-
labeled cDNA probes. Glial RNA levels relative to those of GAPDH were
calculated with Quantity One software from Bio-Rad.
Fig. 5. Aggrecan protein and message are enriched in cells expressing glial
markers. (A, B) E8 chick midbrain cross-sections double-labeled for aggrecan
immunoreactivity (brown) and nestin/NES and GLAST mRNAs (blue). Arrows
point to cells that both contain intracellular aggrecan core protein and express
the glial marker transcripts. (C) Confocal XYprojections of E9 hindbrain cross-
sections processed for fluorescent in situ hybridization (FISH) for aggrecan/
AGC mRNA (green) and for immunohistological localization of the glial
marker BLBP (red). (D) Confocal XY projections of FISH for aggrecan/AGC
mRNA (green) and immunostaining for the astrocyte marker GFAP (red) from
E13 midbrain cross-sections. Confocal overlay projections identify cells ex-
pressing aggrecan and the radial glial marker or the astrocyte marker
(arrowheads). ZY projections of the merged pictures through the marked axes
(white lines) are shown in the left side panels.
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association in mid-embryogenesis between AGC-expressing
cells and cells harboring the glial markers GLAST, GS, BLBP,
NES and tenascin C. The observation that all these mRNA
patterns differ from each other, at least in part, indicated a clear
heterogeneity among these cells, with subpopulations differing
in their patterns of differentiation and perhaps also in their
functions. Faced with this heterogeneity we sought direct
evidence that AGC-rich cells also express glial identity
markers.
Aggrecan-expressing cells are in the glial lineage
Cellular co-expression experiments on E8 chick brainstem
sections established that some cells expressing mRNA markers
of glial identity also contain aggrecan protein. For these
preparations, we employed the species-specific monoclonal
antibody S103L, which recognizes an epitope in the chondroi-
tin-sulfate-binding region of the aggrecan core protein (Krueger
et al., 1990). On tissue sections, S103L immunochemistry
strongly stained intracellular Golgi-associated aggrecan core
protein and diffusely labeled tracts where aggrecan-expressing
cells with migratory morphology are found. Strong S103L
staining was found within cells expressing the glial lineage
markers nestin (Fig. 5A) and GLAST (Fig. 5B), although the
apparent subcellular localization of the mRNAs and the
aggrecan core protein was often distinct.
Despite the Golgi association of the aggrecan immunor-
eactivity, we were concerned that the immunolabeling we saw
could have been glial accumulation of extracellular aggrecan
protein. We addressed this possibility in two ways. First, control
sections hybridized with an AGC probe and immunostained
with S103L antibody demonstrated many co-localization
profiles (Schwartz and Domowicz, 2004). Second, we carried
out two-color fluorescent in situ hybridization combined with
confocal imaging to test for cellular co-expression. Z projec-
tions of cells doubly labeled to detect AGC and either GLASTmRNA or BLBP protein confirmed co-expression of AGC and
the glial markers (Fig. 5C; Fig. S2). Finally, at later stages (E13)
when GFAP is abundant, we could detect AGC-positive cells
expressing GFAP protein (Fig. 5D). Importantly, though, ag-
grecan message was not found in all GLAST- or BLBP-positive
cells, confirming that it is a subpopulation of radial glial cells
that express aggrecan.
We next developed a culture system to explore whether
populations of aggrecan-expressing cells have gliogenic
potential. We harvested VZ tissue from E11 chick midbrain, a
source rich in AGC-expressing cells (Fig. S3). Dissociated cells
plated in DMEM supplemented with EGF and bFGF, divided
rapidly and established a monolayer of AGC-expressing cells
(Fig. 6). This population also expressed NES and BLBP (not
shown) but did not express markers of postmitotic neurons
(TUBB3) or differentiated glial cells (PLP1, GFAP). After 7
days in vitro, we switched the medium to a glial differentiation
formula (DMEM/F12 supplemented with G5 and 1.5 μM
trans-retinoic acid). Two days later, we found a marked increase
in cells expressing the glial markers GS, GLAST and GFAP. We
also saw a sparse population of PLP1-positive cells with
morphologies consistent with those of oligodendrocytes pre-
cursors. As expected, no cells labeled with the neuronal marker
TUBB3 were detected (Fig. 6). Since DNA levels increased
Fig. 6. E11 midbrain VZ cultures enriched in aggrecan-expressing cells have
gliogenic potential. Left panels: Gene expression profiling by in situ
hybridization of VZ cell cultures harvested after 9 days in vitro in DMEM/
10% fetal calf serum with 40 ng/ml EGF and 40 ng/ml bFGF added. This
preparation yielded bulk cultures of aggrecan-expressing cells (AGC) free of
differentiated astrocytes (GLAST, GFAP), neurons (TUBB3) or oligodendrocytes
(PLP1). Right panels: Parallel cultures shifted after 7 days in EGF/bFGF
medium to F12/DMEMwith G5 and 1.5 μM trans-retinoic acid for 2 days. This
shift elicited the induction of the glial markers GLAST, GFAP and PLP1 in the
aggrecan-rich cultures. In situ hybridization demonstration of culture gene
expression was carried out directly on the Primaria culture dishes on which the
cells were grown.
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and no morphological evidence of cell death was observed (data
not shown), we conclude that aggrecan-expressing cells in vitro
have the ability to differentiate into glia.
An aggrecan requirement for normal glial development
Nanomelia (nm) is a mutant chicken line deficient in
aggrecan. Molecular studies have identified an aggrecan gene
frameshift mutation that produces a truncated aggrecan core
protein that is unable to mature through the secretory pathway
(Domowicz et al., 1996; Domowicz et al., 2000; Li et al., 1993;
Vertel et al., 1994). Nanomelic homozygotes do not hatch. At
E17 nm brains had mild hydrocephaly of the lateral ventricles
and a 10% reduction in wet brain weight compared to that ofcontrol flock mates (data not shown). We studied nanomelic
brain development to test for a requirement for aggrecan
function in gliogenesis.
We first assessed quantitative mRNA levels for glial markers
at E20, by which time many astrocyte markers have reached
their maximal levels (Fig. 4). Two-fold increases in GFAP and
GS RNA and a 30% increase in GLAST RNA were found in
nanomelic brain total RNA extracts relative to those prepared
from flock mate controls. By contrast, no changes were
recorded in the levels of the oligodendrocyte marker PLP1 or
the neuronal marker TUBB3 (Fig. 7).
In situ hybridization histology on E17–E21 nanomelic
brains also demonstrated increased levels of the astrocyte
mRNAs GFAP, GS and GLAST in all brain regions examined
(Figs. 8, 9 and data not shown). That increased GFAP protein
expression accompanied the GFAP message rise was shown by
immunocytochemistry (Figs. 9C, F). Interestingly, the distribu-
tion pattern of GFAP was also affected. As illustrated in Fig. 9
for the E18 optic tectum, GFAP mRNA was denser in the VZ
but reduced at the pial surface in nanomelic brains (Figs. 9B, E).
At earlier ages (E12–E15), however, the levels and patterns of
mRNA expression for the glial markers GLAST, GS, NES
and GFAP appeared unchanged in nanomelic brains (data not
shown).
The late embryonic increase in astrocytic gene expression
could have been due to a reactive gliosis secondary to the nm
hydrocephaly or some other indirect trauma to the nanomelic
brain. To address this possibility, we tested for the microglial
activation that accompanies the reactive astrocytic response to
injury. Northern blot analysis of nm and control brains showed
that levels of the microglial marker PTGS2/COX2 in E18 nm
brains were unchanged from those of controls (not shown). It
was also possible that the nm embryos had cerebrovascular
abnormalities that might affect astrocytes whose end-feet
surround the endothelial cells forming the blood–brain barrier.
We imaged the brain circulatory system in E18 chick embryos
by intra-cardiac injection of 100 μl of fluorescein–albumin
(2.5 mg/ml) 5 min before sacrifice. Fluorescence microscopy
analysis of nm brain sections showed intravascular distributions
of fluorescein–albumin similar to those seen in wild type brain
sections, indicating that no major disruption of the blood–brain
barrier occurs in the mutant (not shown). Finally, we repeated
the culturing of VZ cells from E11 nm and normal midbrains.
Nanomelic cultures showed dramatic upregulation of astrocyte
differentiation markers compared to the normal cultures (Fig. 10
and Fig. S4). These data argue that the astrocytic marker
upregulation seen in nanomelic brains is not a result of post-E11
systemic trauma and further supports our hypothesis that
extracellular aggrecan exerts a regulatory effect on astrocyte
differentiation.
The increase in astrocyte gene expression in nm brains could
be due to an increase in astrocyte number, either from increased
cell division or reduced cell death. We looked for increased
proliferation by astrocyte precursor cells in two ways. First,
mitotic figures in E15 and E18 cerebellar white matter were
identified with anti-phosphohistone H3 immunolabeling. No
differences in the densities of mitotic figures were found
Fig. 7. Elevation of astroglial gene expression levels in chick embryos lacking functional aggrecan. (A) Blots of total brain RNA isolated from flock mate (c, left
column) and nanomelic (nm, right column) E20 embryos were hybridized with the [32P]-labeled cDNA probes for GLUL, GFAP, GLAST and PLP1. (B) In a separate
experiment, mRNA levels relative to those of GAPDH were calculated for triplicate independent brain samples from flock mate (c) and nanomelic (nm) E18 embryos.
**pb0.01; *pb0.04 by Student's t-test analysis.
Fig. 8. In situ hybridization experiments demonstrate clear upregulation of
astrocyte-specific gene expression in nanomelic chick embryos. (A–D) GLUL
gene expression is increased in E20 nanomelic brains as demonstrated in sagittal
sections of cerebellum (A, B) and coronal sections of midbrain (C, D). Asterisk
in panel A marks the territory of cerebellar white matter studied in Fig. 11. (E, F)
No change is seen in the expression of the astrocyte marker PLP1 in cross-
sections from E20 midbrain.
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Second, we found no significant increase in the densities of E18
cerebellar white matter cells labeled by BrdU retention 3 h after
a pulse delivery (Fig. 10B). We looked for changes in apoptotic
cell death by measuring the levels of caspase 3/7 activity of
nanomelic and control brain regions at E12, E15 and E18. No
significant differences were seen (Fig. S5). These results
indicate that, in the absence of native aggrecan, astrocyte
gene expression levels, but probably not astrocyte numbers, are
elevated in embryonic brain development.
Discussion
Although CSPGs are major components of embryonic brain
ECM, their functional role in regulating cell behavior during
CNS development remains unknown. We report here several
lines of evidence that indicate a role for the CSPG aggrecan in
avian astrocyte development: (a) the onset of aggrecan
expression in the VZ coincides with the end of neurogenesis
and the beginning of gliogenesis in the developing avian brain
(Tsai et al., 1981a,b); (b) aggrecan is co-expressed with the
radial glial markers BLBP, GLAST and NES, and later in
development is found in GFAP-rich cells; (c) populations of VZ
cells expressing aggrecan can differentiate to GFAP-positive
cells when cultured in differentiation media; and (d) animals
lacking functional aggrecan present marked upregulation of
astrocyte gene expression levels.
For astrocytes, determination of the mechanism regulating
their development has been hindered by a lack of markers to
identify astrocyte precursors in vivo (Liu and Rao, 2004; Zhang,
2001). Our findings add aggrecan to the list of native astrocyte
precursor markers. In addition, our observation of partially
overlapping patterns of radial glia and astrocyte precursor
marker expression suggests the presence of multiple subpopula-
tions of astrocyte precursors as has been proposed for neural
Fig. 9. Spatial distributions of the astrocyte marker GFAP are altered in nanomelic embryonic brains. Illustrated are GFAP in situ hybridization experiments on coronal
sections from wild type (A–C) and nanomelic (D–F) E18 midbrain. Boxes in panels A and D indicate areas of optic tectum presented at higher magnification in panels
B and E, respectively. Note that levels of GFAP at the VZ are increased (left side, B and E) and those near and at the pial surface are decreased (right side, B and E) in
the nanomelic (E) as compared with the wt control (B) tissue. Immunocytochemistry with GFAP antibody confirmed increased expression of GFAP protein in the
nanomelic midbrain (F) compared with wild type (C). Sections were counter-stained with DAPI.
121M.S. Domowicz et al. / Developmental Biology 315 (2008) 114–124precursors (Gal et al., 2006). Astrocytes with radically different
functions have been described in adult brain (for example,
perineuronal and perivascular astrocytes) (Hartfuss et al., 2001;Fig. 10. E11 midbrain VZ cultures from nanomelic (nm) embryos exhibited
elevated astroglial gene expression with respect to flock mate control (c) levels.
Left panels: Expression of AGC and GFAP detected by in situ hybridization in
VZ cell cultures harvested after 9 days in vitro in DMEM/10% fetal calf serum
with 40 ng/ml EGF and 40 ng/ml bFGF added. Right panels: Expression of AGC
and GFAP detected by in situ hybridization in parallel VZ cultures maintained
for 7 days in EGF/bFGF medium then shifted to F12/DMEM with G5 and
1.5 μM trans-retinoic acid for 2 days.Haydon and Carmignoto, 2006), but distinctions in astrocyte
subclass developmental origin remain an open question. Our
results suggest strongly that further astrocyte expression
profiling will help delineate subpopulations of functionally
distinct astrocytes that may differ in their developmental
origins.
The increase in astrocyte marker expression in nanomelic
chick embryos could be due to a variety of causes: a rise in glial
progenitor numbers, an increase in the rate or degree of
astrocyte differentiation or possibly a reactive gliosis. With
respect to an increase in astrocytic marker expression due to
trauma, we found that expression of a microglial marker that
accompanies the macroglial response in injury (Ridet et al.,
1997) does not change in nanomelic brains. Furthermore,
cerebrovascular abnormalities or a massive neuronal loss that
might trigger an injury response (Johnston et al., 2001; Joseph
et al., 1992; Taylor et al., 1999) were not observed. The
possibility that aggrecan regulates glial precursor cell division
is an important one since an increased cell cycle rate has been
observed in the nanomelic cartilage, a tissue that normally
expresses high levels of aggrecan (Wong et al., 1992).
However, no significant increase in cell proliferation could
be documented in nanomelic brains using two independent
measurements. Our findings therefore favor the conclusion that
aggrecan influences astrocyte differentiation independent of
astrocyte cell numbers.
Examples in the literature of genetic defects producing
increased astrocyte numbers or gene expression levels are
limited. FGFR3 knockout mice have increased numbers of
astrocytes in the gray matter, suggesting a role for the FGF
pathway in astrocyte-precursor populations (Pringle et al.,
2003). CD81 null mice develop an increased number of
astrocytes and microglia that in turn produce larger brains,
possibly due to lack of proliferation control secondary to
alterations in contact inhibition mechanisms (Geisert et al.,
Fig. 11. Quantitation of cell proliferation markers in cerebellar white matter suggests that increased cell division cannot account for the increase in astrocyte gene
expression levels seen in nanomelia. (A) Densities of phosphohistone H3-positive cells at E15 and E18 are unchanged between nanomelics (nm) and flock mate
controls (c). (B) Densities of BrdU-labeled cells 4 h after a BrdU pulse are not significantly increased in E18 nanomelic cerebellar white matter. Insets show
representative pictures of E15 phosphohistone H3-positive cells and E18 BrdU-labeled cells from nanomelics (nm) and flock mate controls (c). Student's t-test
analysis indicated no significant difference.
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Mash1 exhibit premature and excessive generation of astrocytic
precursors at the expense of the pool of neuronal precursors
(Nieto et al., 2001). Our findings add the CSPG aggrecan to this
short list of astrocyte developmental regulators. In particular,
our observations in the nanomelic mutant are supported by a
recent study showing that non-specific degradation of CSPGs in
the VZ alters the self-renewing capacity of radial glia,
diminishes neurogenesis and increases astrogenesis (Sirko et
al., 2007). These results, together with the finding of late VZ
expression of the CSPG brevican (Jaworski et al., 1995), raise
the possibility that CSPGs apart from aggrecan may also
participate in gliogenesis.
Our findings suggest that a subpopulation of astrocyte
precursors regulate astrocyte differentiation through extracel-
lular matrix signaling mechanisms involving aggrecan. How
might aggrecan act? One mechanism could be that aggrecan
directly regulates the concentration of extracellular growth
factors involved in glial differentiation, possibly by sequestra-
tion. Notable in this regard is the finding from in vitro studies
that heavily sulfated CS chains can bind the midkine family
members (midkine and pleiotrophin), and some FGF family
members (FGF-1, -2, -16, -18) (Deepa et al., 2002; Umehara et
al., 2004). Alternatively, aggrecan may, like other members of
the aggrecan family, bind directly to other glial-derived matrix
components such as tenascin C and modulate their activity
(Rauch, 2004; Yamaguchi, 2000). Perhaps by shaping the
composition of the ECM, aggrecan could affect cell migratory
patterns and change the signaling environment that glial
precursors encounter. Independent of speculations about
mechanism, however, our data provide direct genetic evidence
that the composition of the embryonic brain extracellular matrix
regulates glial cell differentiation.Acknowledgments
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